New York University School of Medicine, NY, USA.
J Subst Abuse Treat. 2012 Dec;43(4):458-62. doi: 10.1016/j.jsat.2012.08.012. Epub 2012 Sep 15.
The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38 weeks total (range, 16-72 weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0 drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).
长期缓释纳曲酮（XR-NTX）酒精治疗的可行性尚不清楚。在初级保健中单臂观察性试验的初始 12 周后，我们在两个公共初级保健诊所中提供了 48 周的 XR-NTX 治疗（另外 12 个月的注射）作为自然延伸研究。在开始接受 XR-NTX 治疗的 65 名酒精依赖成年人中，有 40 名（62%）完成了最初的 12 周 XR-NTX 观察性试验，有 19 名（29%）继续治疗中位数为 38 周（范围 16-72 周；中位数 8 总 XR-NTX 注射）。在积极的扩展阶段参与者中，自我报告的饮酒天数（与治疗前 30 天基线相比）较低：中位数 0.2 与 6.0 饮料/天；82%与 38%的天数戒酒；11%与 61%的重度饮酒天数。在初级保健 MM 模型中进行长期 XR-NTX 治疗是可行的，并且可能促进持续减少饮酒或戒酒（临床试验：NCT00620750）。
